{
  "abstract": "Purpose: Metastatic pheochromocytomas and paragangliomas (mPPGLs) are rare neuroendocrine tumours with limited therapeutic options. Peptide receptor radionuclide therapy (PRRT) using somatostatin receptor (SSTR) antagonists (e.g. [177Lu]Lu-DOTA-JR11) may achieve higher tumour and organ absorbed doses compared with standard SSTR agonist therapy (e.g. [177Lu]Lu-DOTA-TOC). This study aimed to perform an intra-patient comparison of tumour and organ dosimetry between [177Lu]Lu-DOTA-TOC and [177Lu]Lu-DOTA-JR11 in patients with mPPGLs refractory to conventional therapies. Secondary endpoints included safety and exploratory clinical efficacy of [177Lu]Lu-DOTA-JR11.\n\nMethods: In this retrospective pilot study, 6 patients with mPPGLs received 1–2 cycles of [177Lu]Lu-DOTA-TOC (~ 7.4 GBq/cycle), followed by 1–2 cycles of [177Lu]Lu-DOTA-JR11 (2 GBq/m2 × body surface area) at an interval of 10–12 weeks. Endpoints included estimation of tumour and organ absorbed doses, assessment of safety according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and symptoms, and evaluation of progression-free survival (PFS) before and after [177Lu]Lu-DOTA-JR11 therapy.\n\nResults: Intra-patient comparison showed that the median tumour absorbed dose per cycle was 1.3-fold higher (range 0.9–3.5) with [177Lu]Lu-DOTA-JR11 than with [177Lu]Lu-DOTA-TOC. This was associated with longer PFS after [177Lu]Lu-DOTA-JR11 (12.5 months; range 6 – >20) versus PFS before inclusion (3.5 months; range 1–9). The most severe adverse event was grade 3 lymphopenia in one patient. No thrombocytopenia, neutropenia, creatinine elevation or alanine aminotransferase elevation was observed.\n\nConclusion: [177Lu]Lu-DOTA-JR11 resulted in higher tumour absorbed doses than [177Lu]Lu-DOTA-TOC and was associated with longer post-treatment PFS than PFS before inclusion in this small cohort. Treatment was well tolerated, supporting further prospective evaluation in patients with mPPGLs.",
  "abstract_shown": true,
  "affiliations": [
    "Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, Basel, CH-4031 Switzerland",
    "“Ana Aslan” National Institute of Geriatrics and Gerontology, Bucharest, Romania",
    "Department of Medical Radiation Sciences, Institution of Clinical Science, University of Gothenburg, Gothenburg, Sweden",
    "ENETS Center of Excellence for Neuroendocrine and Endocrine Tumours, University Hospital Basel, Basel, Switzerland",
    "Department of Endocrinology, University Hospital Basel, Basel, Switzerland"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 10,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Felix Schmidt"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Sofia-Maria Lider"
    },
    {
      "affs": [
        0
      ],
      "name": "Lisa McDougall"
    },
    {
      "affs": [
        0
      ],
      "name": "Christopher Eigler"
    },
    {
      "affs": [
        2
      ],
      "name": "Peter Bernhardt"
    },
    {
      "affs": [
        0
      ],
      "name": "Abdulrafee Mushaweh"
    },
    {
      "affs": [
        0
      ],
      "name": "Andreas Bauman"
    },
    {
      "affs": [
        0
      ],
      "name": "Melpomeni Fani"
    },
    {
      "affs": [
        3,
        4
      ],
      "name": "Emanuel Christ"
    },
    {
      "affs": [
        0,
        3
      ],
      "name": "Damian Wild",
      "orcid": "0000-0002-8135-5350"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/276h6hdxf2d5d.bib",
  "cited_by": 0,
  "doi": "10.1007/s00259-026-08122-8",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13727916/",
  "id": "276h6hdxf2d5d",
  "issns": [
    "1619-7070",
    "1619-7089"
  ],
  "landing_url": "https://doi.org/10.1007/s00259-026-08122-8",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Article"
    ],
    [
      "openalex",
      "2741|Radiopharmaceutical Chemistry and Applications"
    ]
  ],
  "openalex": "W7202172768",
  "pdf_url": "https://link.springer.com/content/pdf/10.1007/s00259-026-08122-8.pdf",
  "pmcid": "PMC13727916",
  "pmid": "42581163",
  "published": "2026-08-12",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/276h6hdxf2d5d.ris",
  "sources": [
    {
      "first_seen": "2026-11-06T12:23:42Z",
      "native_id": "PMC13727916",
      "source": "pmc",
      "url": "https://doi.org/10.1007/s00259-026-08122-8"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2741|Radiopharmaceutical Chemistry and Applications",
      "subfield": "imaging"
    }
  ],
  "title": "Radiolabelled somatostatin receptor antagonist versus agonist for peptide receptor radionuclide therapy in patients with metastatic pheochromocytoma or paraganglioma: a retrospective pilot study",
  "title_text": "Radiolabelled somatostatin receptor antagonist versus agonist for peptide receptor radionuclide therapy in patients with metastatic pheochromocytoma or paraganglioma: a retrospective pilot study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-06T12:23:42Z",
  "url": "https://research.draconitic.com/paper/276h6hdxf2d5d",
  "venue": "European Journal of Nuclear Medicine and Molecular Imaging",
  "versions": []
}